- The US FDA has granted approval to PerkinElmer's ( NYSE: PKI ) EONIS SCID-SMA assay kit for in vitro diagnostic (IVD) use for spinal muscular atrophy ( SMA ) and severe combined immunodeficiency ( SCID ) in newborns.
- The platform uses PCR technology to screen for both SMA and SCID using a single dried blood spot sample, combining DNA extraction and multiplexing.
- EONIS is also CE-IVD marked for use.
- Read why Seeking Alpha contributor The Value Investor views PerkinElmer ( PKI ) as a buy.
For further details see:
PerkinElmer receives FDA approval for EONIS assay for spinal muscular atrophy in newborns